1 | retrospective | 9,141 |
2 | post-hoc | 905 |
3 | two-part | 125 |
4 | posthoc | 58 |
5 | cost-minimization | 55 |
6 | three-part | 32 |
7 | cost-consequence | 21 |
8 | five-part | 9 |
9 | drug-utilization | 5 |
10 | pooled-data | 5 |
11 | restrospective | 5 |
12 | prospectively-collected | 4 |
13 | microgenetic | 3 |
14 | nonrepresentative | 3 |
15 | obesity.this | 3 |
16 | person-linked | 3 |
17 | random-sampled | 3 |
18 | segment-by-segment | 3 |
19 | stereolithographic | 3 |
20 | .vtk | 2 |
21 | best-rank | 2 |
22 | choice-format | 2 |
23 | contact-time | 2 |
24 | disease-level | 2 |
25 | fib/sem | 2 |
26 | granulometric | 2 |
27 | included.subgroup | 2 |
28 | interventions.this | 2 |
29 | kantian | 2 |
30 | lesion-by-lesion | 2 |
31 | lyon-sud | 2 |
32 | matched-case | 2 |
33 | non-suppressed | 2 |
34 | polysomnograph | 2 |
35 | population-controlled | 2 |
36 | power-lab | 2 |
37 | preformatted | 2 |
38 | retrospectives | 2 |
39 | single-hospital-based | 2 |
40 | surgery.this | 2 |
41 | tab-delimited | 2 |
42 | wilcoxon-rank | 2 |
43 | 'worst-best | 1 |
44 | //links.lww.com/coe/a9 | 1 |
45 | 1.25-year | 1 |
46 | 10-l | 1 |
47 | 12-patient | 1 |
48 | 2-layered | 1 |
49 | 2000-07 | 1 |
50 | 3.0-4.0-cm | 1 |
51 | 3×2×2 | 1 |
52 | 4-head | 1 |
53 | 5-country | 1 |
54 | 5.5ml | 1 |
55 | 7-patient | 1 |
56 | 7.6-cm | 1 |
57 | 73-patient | 1 |
58 | belgian/dutch | 1 |
59 | best-worst-case-scenario | 1 |
60 | bronchodilator-responsive | 1 |
61 | by-time-point | 1 |
62 | card-sized | 1 |
63 | case.control | 1 |
64 | charge-effectiveness | 1 |
65 | child-protection | 1 |
66 | clinical-epidemiologic | 1 |
67 | combined-sex | 1 |
68 | context-mechanism-outcome | 1 |
69 | convection-dominated | 1 |
70 | correlation-regression | 1 |
71 | cost-effectivity | 1 |
72 | cost-wise | 1 |
73 | cost–benefit | 1 |
74 | covariate-free | 1 |
75 | deep-time | 1 |
76 | drug-reimbursement | 1 |
77 | dual-trajectory | 1 |
78 | exchange-only | 1 |
79 | feminist-oriented | 1 |
80 | ferris-bailey | 1 |
81 | free-wilson | 1 |
82 | gene-wise | 1 |
83 | genotype-by-interaction | 1 |
84 | glycotranscriptomic | 1 |
85 | highly-aggressive | 1 |
86 | highly-interconnected | 1 |
87 | iii-retrospective | 1 |
88 | indication.a | 1 |
89 | keratomycosis | 1 |
90 | l-idofuranoside | 1 |
91 | locally-driven | 1 |
92 | low-baseline-fmd | 1 |
93 | low-to-moderate-risk | 1 |
94 | medication-level | 1 |
95 | meek | 1 |
96 | men.this | 1 |
97 | mercaptoacetyltriglycine-lasix | 1 |
98 | meta-content | 1 |
99 | metabolic/cardiovascular | 1 |
100 | micro-cost | 1 |
101 | modest-quality | 1 |
102 | multi-endpoint | 1 |
103 | multi-institute | 1 |
104 | multiblocks | 1 |
105 | near-equilibrium | 1 |
106 | non-degenerative | 1 |
107 | non-ecmo | 1 |
108 | non-mechanistic | 1 |
109 | nonbacklit | 1 |
110 | nurse-and-teacher | 1 |
111 | observa- | 1 |
112 | one-hla-dr | 1 |
113 | one-institution | 1 |
114 | op-ed | 1 |
115 | outpatient/day | 1 |
116 | partitioned-survival | 1 |
117 | per-kilogram | 1 |
118 | pharmaco-morbidity | 1 |
119 | plaque-control | 1 |
120 | porosity-permeability | 1 |
121 | practice.qualitative | 1 |
122 | pre-birth | 1 |
123 | pre-completed | 1 |
124 | pre-enrolled | 1 |
125 | preposterior | 1 |
126 | priori-designed | 1 |
127 | profile-likelihood | 1 |
128 | protocol-planned | 1 |
129 | pyrolysis-gc/ms | 1 |
130 | quasi-historical | 1 |
131 | randcastle | 1 |
132 | readme | 1 |
133 | redundance | 1 |
134 | retropective | 1 |
135 | retrospetive | 1 |
136 | section-by-section | 1 |
137 | serial-measures | 1 |
138 | seroprevalent | 1 |
139 | sex-stimulating | 1 |
140 | snelen | 1 |
141 | statistical/endpoint | 1 |
142 | strut-based | 1 |
143 | swedish-caucasian | 1 |
144 | technoeconomic | 1 |
145 | time-sequenced | 1 |
146 | time/intensity | 1 |
147 | toxin-experienced | 1 |
148 | univaried | 1 |
149 | vessel-based | 1 |
150 | walk-through | 1 |
151 | whole-service | 1 |
152 | within-the-table | 1 |
153 | wopacom | 1 |
154 | worst-best-case-scenario | 1 |
1 | 'worst-best | 1 |
2 | .vtk | 2 |
3 | //links.lww.com/coe/a9 | 1 |
4 | 1.25-year | 1 |
5 | 10-l | 1 |
6 | 12-patient | 1 |
7 | 2-layered | 1 |
8 | 2000-07 | 1 |
9 | 3.0-4.0-cm | 1 |
10 | 3×2×2 | 1 |
11 | 4-head | 1 |
12 | 5-country | 1 |
13 | 5.5ml | 1 |
14 | 7-patient | 1 |
15 | 7.6-cm | 1 |
16 | 73-patient | 1 |
17 | belgian/dutch | 1 |
18 | best-rank | 2 |
19 | best-worst-case-scenario | 1 |
20 | bronchodilator-responsive | 1 |
21 | by-time-point | 1 |
22 | card-sized | 1 |
23 | case.control | 1 |
24 | charge-effectiveness | 1 |
25 | child-protection | 1 |
26 | choice-format | 2 |
27 | clinical-epidemiologic | 1 |
28 | combined-sex | 1 |
29 | contact-time | 2 |
30 | context-mechanism-outcome | 1 |
31 | convection-dominated | 1 |
32 | correlation-regression | 1 |
33 | cost-consequence | 21 |
34 | cost-effectivity | 1 |
35 | cost-minimization | 55 |
36 | cost-wise | 1 |
37 | cost–benefit | 1 |
38 | covariate-free | 1 |
39 | deep-time | 1 |
40 | disease-level | 2 |
41 | drug-reimbursement | 1 |
42 | drug-utilization | 5 |
43 | dual-trajectory | 1 |
44 | exchange-only | 1 |
45 | feminist-oriented | 1 |
46 | ferris-bailey | 1 |
47 | fib/sem | 2 |
48 | five-part | 9 |
49 | free-wilson | 1 |
50 | gene-wise | 1 |
51 | genotype-by-interaction | 1 |
52 | glycotranscriptomic | 1 |
53 | granulometric | 2 |
54 | highly-aggressive | 1 |
55 | highly-interconnected | 1 |
56 | iii-retrospective | 1 |
57 | included.subgroup | 2 |
58 | indication.a | 1 |
59 | interventions.this | 2 |
60 | kantian | 2 |
61 | keratomycosis | 1 |
62 | l-idofuranoside | 1 |
63 | lesion-by-lesion | 2 |
64 | locally-driven | 1 |
65 | low-baseline-fmd | 1 |
66 | low-to-moderate-risk | 1 |
67 | lyon-sud | 2 |
68 | matched-case | 2 |
69 | medication-level | 1 |
70 | meek | 1 |
71 | men.this | 1 |
72 | mercaptoacetyltriglycine-lasix | 1 |
73 | meta-content | 1 |
74 | metabolic/cardiovascular | 1 |
75 | micro-cost | 1 |
76 | microgenetic | 3 |
77 | modest-quality | 1 |
78 | multi-endpoint | 1 |
79 | multi-institute | 1 |
80 | multiblocks | 1 |
81 | near-equilibrium | 1 |
82 | non-degenerative | 1 |
83 | non-ecmo | 1 |
84 | non-mechanistic | 1 |
85 | non-suppressed | 2 |
86 | nonbacklit | 1 |
87 | nonrepresentative | 3 |
88 | nurse-and-teacher | 1 |
89 | obesity.this | 3 |
90 | observa- | 1 |
91 | one-hla-dr | 1 |
92 | one-institution | 1 |
93 | op-ed | 1 |
94 | outpatient/day | 1 |
95 | partitioned-survival | 1 |
96 | per-kilogram | 1 |
97 | person-linked | 3 |
98 | pharmaco-morbidity | 1 |
99 | plaque-control | 1 |
100 | polysomnograph | 2 |
101 | pooled-data | 5 |
102 | population-controlled | 2 |
103 | porosity-permeability | 1 |
104 | post-hoc | 905 |
105 | posthoc | 58 |
106 | power-lab | 2 |
107 | practice.qualitative | 1 |
108 | pre-birth | 1 |
109 | pre-completed | 1 |
110 | pre-enrolled | 1 |
111 | preformatted | 2 |
112 | preposterior | 1 |
113 | priori-designed | 1 |
114 | profile-likelihood | 1 |
115 | prospectively-collected | 4 |
116 | protocol-planned | 1 |
117 | pyrolysis-gc/ms | 1 |
118 | quasi-historical | 1 |
119 | randcastle | 1 |
120 | random-sampled | 3 |
121 | readme | 1 |
122 | redundance | 1 |
123 | restrospective | 5 |
124 | retropective | 1 |
125 | retrospective | 9,141 |
126 | retrospectives | 2 |
127 | retrospetive | 1 |
128 | section-by-section | 1 |
129 | segment-by-segment | 3 |
130 | serial-measures | 1 |
131 | seroprevalent | 1 |
132 | sex-stimulating | 1 |
133 | single-hospital-based | 2 |
134 | snelen | 1 |
135 | statistical/endpoint | 1 |
136 | stereolithographic | 3 |
137 | strut-based | 1 |
138 | surgery.this | 2 |
139 | swedish-caucasian | 1 |
140 | tab-delimited | 2 |
141 | technoeconomic | 1 |
142 | three-part | 32 |
143 | time-sequenced | 1 |
144 | time/intensity | 1 |
145 | toxin-experienced | 1 |
146 | two-part | 125 |
147 | univaried | 1 |
148 | vessel-based | 1 |
149 | walk-through | 1 |
150 | whole-service | 1 |
151 | wilcoxon-rank | 2 |
152 | within-the-table | 1 |
153 | wopacom | 1 |
154 | worst-best-case-scenario | 1 |
1 | observa- | 1 |
2 | 3×2×2 | 1 |
3 | 2000-07 | 1 |
4 | //links.lww.com/coe/a9 | 1 |
5 | indication.a | 1 |
6 | pooled-data | 5 |
7 | power-lab | 2 |
8 | clinical-epidemiologic | 1 |
9 | stereolithographic | 3 |
10 | technoeconomic | 1 |
11 | glycotranscriptomic | 1 |
12 | granulometric | 2 |
13 | microgenetic | 3 |
14 | non-mechanistic | 1 |
15 | post-hoc | 905 |
16 | posthoc | 58 |
17 | 4-head | 1 |
18 | op-ed | 1 |
19 | toxin-experienced | 1 |
20 | time-sequenced | 1 |
21 | univaried | 1 |
22 | person-linked | 3 |
23 | pre-enrolled | 1 |
24 | population-controlled | 2 |
25 | random-sampled | 3 |
26 | priori-designed | 1 |
27 | protocol-planned | 1 |
28 | 2-layered | 1 |
29 | single-hospital-based | 2 |
30 | vessel-based | 1 |
31 | strut-based | 1 |
32 | non-suppressed | 2 |
33 | convection-dominated | 1 |
34 | prospectively-collected | 4 |
35 | highly-interconnected | 1 |
36 | pre-completed | 1 |
37 | tab-delimited | 2 |
38 | feminist-oriented | 1 |
39 | preformatted | 2 |
40 | card-sized | 1 |
41 | low-baseline-fmd | 1 |
42 | profile-likelihood | 1 |
43 | lyon-sud | 2 |
44 | whole-service | 1 |
45 | redundance | 1 |
46 | cost-consequence | 21 |
47 | l-idofuranoside | 1 |
48 | covariate-free | 1 |
49 | within-the-table | 1 |
50 | randcastle | 1 |
51 | readme | 1 |
52 | deep-time | 1 |
53 | contact-time | 2 |
54 | context-mechanism-outcome | 1 |
55 | matched-case | 2 |
56 | gene-wise | 1 |
57 | cost-wise | 1 |
58 | multi-institute | 1 |
59 | bronchodilator-responsive | 1 |
60 | highly-aggressive | 1 |
61 | non-degenerative | 1 |
62 | practice.qualitative | 1 |
63 | nonrepresentative | 3 |
64 | retropective | 1 |
65 | retrospective | 9,141 |
66 | iii-retrospective | 1 |
67 | restrospective | 5 |
68 | retrospetive | 1 |
69 | sex-stimulating | 1 |
70 | belgian/dutch | 1 |
71 | walk-through | 1 |
72 | polysomnograph | 2 |
73 | pre-birth | 1 |
74 | meek | 1 |
75 | wilcoxon-rank | 2 |
76 | best-rank | 2 |
77 | low-to-moderate-risk | 1 |
78 | .vtk | 2 |
79 | 10-l | 1 |
80 | quasi-historical | 1 |
81 | partitioned-survival | 1 |
82 | disease-level | 2 |
83 | medication-level | 1 |
84 | 5.5ml | 1 |
85 | plaque-control | 1 |
86 | case.control | 1 |
87 | per-kilogram | 1 |
88 | 3.0-4.0-cm | 1 |
89 | 7.6-cm | 1 |
90 | fib/sem | 2 |
91 | wopacom | 1 |
92 | near-equilibrium | 1 |
93 | swedish-caucasian | 1 |
94 | kantian | 2 |
95 | snelen | 1 |
96 | locally-driven | 1 |
97 | lesion-by-lesion | 2 |
98 | correlation-regression | 1 |
99 | drug-utilization | 5 |
100 | cost-minimization | 55 |
101 | genotype-by-interaction | 1 |
102 | section-by-section | 1 |
103 | child-protection | 1 |
104 | one-institution | 1 |
105 | free-wilson | 1 |
106 | worst-best-case-scenario | 1 |
107 | best-worst-case-scenario | 1 |
108 | non-ecmo | 1 |
109 | included.subgroup | 2 |
110 | 1.25-year | 1 |
111 | metabolic/cardiovascular | 1 |
112 | one-hla-dr | 1 |
113 | nurse-and-teacher | 1 |
114 | preposterior | 1 |
115 | serial-measures | 1 |
116 | retrospectives | 2 |
117 | men.this | 1 |
118 | interventions.this | 2 |
119 | surgery.this | 2 |
120 | obesity.this | 3 |
121 | keratomycosis | 1 |
122 | multiblocks | 1 |
123 | pyrolysis-gc/ms | 1 |
124 | charge-effectiveness | 1 |
125 | choice-format | 2 |
126 | cost–benefit | 1 |
127 | nonbacklit | 1 |
128 | 12-patient | 1 |
129 | 73-patient | 1 |
130 | 7-patient | 1 |
131 | seroprevalent | 1 |
132 | drug-reimbursement | 1 |
133 | segment-by-segment | 3 |
134 | meta-content | 1 |
135 | by-time-point | 1 |
136 | multi-endpoint | 1 |
137 | statistical/endpoint | 1 |
138 | three-part | 32 |
139 | five-part | 9 |
140 | two-part | 125 |
141 | 'worst-best | 1 |
142 | micro-cost | 1 |
143 | combined-sex | 1 |
144 | mercaptoacetyltriglycine-lasix | 1 |
145 | outpatient/day | 1 |
146 | ferris-bailey | 1 |
147 | exchange-only | 1 |
148 | dual-trajectory | 1 |
149 | 5-country | 1 |
150 | pharmaco-morbidity | 1 |
151 | modest-quality | 1 |
152 | porosity-permeability | 1 |
153 | time/intensity | 1 |
154 | cost-effectivity | 1 |